Search details
1.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol
; 25(2): 212-224, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38134948
2.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Article
in English
| MEDLINE | ID: mdl-38447003
3.
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4073-4083, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38459418
4.
German, Austrian, and Swiss guidelines for systemic treatment of gastric cancer.
Gastric Cancer
; 27(1): 6-18, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37847333
5.
ADJUBIL: phase II study of adjuvant immunotherapy with STRIDE regimen with/without capecitabine in biliary tract cancers.
Future Oncol
; 20(6): 307-315, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-38410920
6.
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Int J Cancer
; 153(10): 1726-1733, 2023 11 15.
Article
in English
| MEDLINE | ID: mdl-37455496
7.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer
; 153(1): 153-163, 2023 07 01.
Article
in English
| MEDLINE | ID: mdl-36883420
8.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC Cancer
; 23(1): 561, 2023 Jun 19.
Article
in English
| MEDLINE | ID: mdl-37337155
9.
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
Int J Cancer
; 150(6): 1007-1017, 2022 03 15.
Article
in English
| MEDLINE | ID: mdl-34741530
10.
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Br J Cancer
; 127(5): 836-843, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35637412
11.
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
Future Oncol
; 18(20): 2465-2473, 2022 Jun.
Article
in English
| MEDLINE | ID: mdl-35535555
12.
Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group.
Int J Cancer
; 149(6): 1322-1331, 2021 09 15.
Article
in English
| MEDLINE | ID: mdl-34019698
13.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Article
in English
| MEDLINE | ID: mdl-33038277
14.
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Oncologist
; 26(10): e1704-e1729, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34288262
15.
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
BMC Cancer
; 21(1): 1158, 2021 Oct 29.
Article
in English
| MEDLINE | ID: mdl-34715810
16.
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma.
Gastric Cancer
; 24(3): 721-730, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33755863
17.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Int J Cancer
; 147(9): 2493-2502, 2020 11 01.
Article
in English
| MEDLINE | ID: mdl-32339253
18.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Article
in English
| MEDLINE | ID: mdl-30982686
19.
Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2-Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Oncologist
; 25(8): e1181-e1187, 2020 08.
Article
in English
| MEDLINE | ID: mdl-32311799
20.
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
BMC Cancer
; 20(1): 886, 2020 Sep 15.
Article
in English
| MEDLINE | ID: mdl-32933498